The ReSToRe Team Supports World MS Day

Today is World MS Day! That is the day to celebrate global solidarity and hope for all people living with MS. With the entire international ReSToRe team, we are committed to find a solution for this devastating disease by bringing an antigen-specific tolerance-inducing dendritic cell (tolDC) therapy to treat MS patients to the clinic. Today, we are preparing for a phase 2 clinical trial in which information about effectiveness of the treatment will be collected. By connecting researchers, clinicians and patients, the ReSToRe consortium is helping to build a community that strives to beat MS.

We Present at the 2023 Annual Meeting of the CMSC

CMSC is the organization of healthcare professionals committed to providing optimal service to everyone affected by MS. They meet each year to discuss the progress of MS research and care. We are pleased that the organizers of the 2023 Annual Meeting, to be held in June in Aurora, Colorado, have given us the opportunity to present ReStoRe’s research. Our researcher, Barbara Willekens, PhD, will give a presentation entitled ‘Intradermal and Intranodal Administration of Vitamin D3-Induced Tolerogenic Dendritic Cells Is Safe and Feasible in Two Phase I Clinical Trials’ on June 2, 2023 at 3:05 PM.

5th annual consortium meeting

On Friday 27/1, the consortium convened in Antwerp, after more than 2 years of virtual meetings. At this meeting, we welcomed our external scientific experts, members of the Data Safety Monitoring Board and the Stakeholder Committee and provided them with an overview of the Phase I clinical trial, which we have successfully completed. In addition, we looked ahead to the coming years, in particular the start of the Phase II trial. Again, it was a very interesting meeting.

Update on the Phase II Clinical Trial

The phase II clinical trial application is successfully submitted at the ethical committee and national competent authorities. We expect their feedback within the next 90 days.

The Fifth Consortium Meeting is postponed

The 5th annual consortium meeting, which was planned in December 2022, is postponed to early 2023. During this meeting we will provide our stakeholders with a complete overview of the acquired data from phase 1.

Congratulations to Frederico Fondelli

PhD students Federico Fondelli from the Catalan Institute of Health (ICS) has been awarded for the best oral presentation ‘Influence of Multiple Sclerosis inflammatory context in the development of a tolerogenic dendritic cell therapy’ at the XVI Congress of the Catalan Society of Immunology, held in Barcelona on November 24-25, 2022. During his presentation, he referred to ReSToRe’s ongoing work as a potential new therapy for MS.